Trials / Completed
CompletedNCT01012375
Study to Investigate the Efficacy and Tolerability of AZD1446 in Adult ADHD Patients.
A Phase IIa, Multi-center, Randomized, Double-blind, Placebo-controlled, Cross-Over Study to Assess the Efficacy, Safety ,Tolerability and Pharmacokinetics of Three Oral AZD1446 Dose Regimens and Placebo During 2 Weeks of Treatment in Adult Non-Users and Users of Nicotine Containing Products
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 135 (actual)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether 2 weeks of treatment with AZD1446 compared to placebo improves ADHD symptoms and is well tolerated.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AZD1446 | 10 mg capsule, oral dose |
| DRUG | AZD1446 | 80 mg capsule, oral dose |
| DRUG | AZD1446 | 80 mg capsule, oral dose |
| DRUG | Placebo | Matching capsule, oral dose |
Timeline
- Start date
- 2009-11-01
- Primary completion
- 2010-08-01
- Completion
- 2010-08-01
- First posted
- 2009-11-13
- Last updated
- 2011-09-02
Locations
6 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01012375. Inclusion in this directory is not an endorsement.